ProCE Banner Activity

Phase I/II BRUIN Trial of LOXO-305 in Previously Treated Patients With CLL/SLL

Slideset Download
Conference Coverage
Updated results of the next-generation, noncovalent BTK inhibitor LOXO-305 suggest encouraging efficacy and safety in heavily pretreated patients with CLL/SLL.

Released: December 17, 2020

Expiration: December 16, 2021

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Amgen, Inc.

AstraZeneca

Bristol Myers Squibb

Epizyme, Inc.

GlaxoSmithKline

Incyte Corporation

Janssen Biotech

Karyopharm Therapeutics Inc.

Novartis

PharmaEssentia Corp

Seagen

Takeda Oncology